|
|
Article: Biotech Holdings patent rights strengthened by new United States patent.(Brief Article)
- Article from:
- BIOTECH Patent News
- Article date:
- October 1, 2001
CopyrightCOPYRIGHT 2001 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
President of Biotech Holdings (Vancouver, Canada; 888-216-1111) announced that a United States Patent 6,291,495, detailing methods for use of insulin-sensitizing drugs in combination therapies for treatment of all forms of diabetes, was granted to him on September 18, 2001. Simultaneously, Mr. Rieveley announced that he has assigned to Biotech Holdings Ltd. ("Biotech") all rights relating to DIAB II that arise from this new United States patent.
"I am pleased to announce that I have assigned to Biotech Holdings Ltd. all patent rights for use of DIAB II that arise from this new patent . The assignment of rights is for the twenty-year life of the patent and ...